EA201001143A1 - Активаторы прокаспаз "исполнителей" 3, 6 и 7 - Google Patents

Активаторы прокаспаз "исполнителей" 3, 6 и 7

Info

Publication number
EA201001143A1
EA201001143A1 EA201001143A EA201001143A EA201001143A1 EA 201001143 A1 EA201001143 A1 EA 201001143A1 EA 201001143 A EA201001143 A EA 201001143A EA 201001143 A EA201001143 A EA 201001143A EA 201001143 A1 EA201001143 A1 EA 201001143A1
Authority
EA
Eurasian Patent Office
Prior art keywords
activators
executors
performers
compounds
methods
Prior art date
Application number
EA201001143A
Other languages
English (en)
Inventor
Джим Уэллс
Адам Р. Ренсло
Деннис Уолан
Джули Зорн
Original Assignee
Те Риджентс Оф Те Юниверсити Оф Калифорния
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Те Риджентс Оф Те Юниверсити Оф Калифорния filed Critical Те Риджентс Оф Те Юниверсити Оф Калифорния
Publication of EA201001143A1 publication Critical patent/EA201001143A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/12—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 3 and unsubstituted in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Настоящее изобретение относится к соединениям, применимым в качестве активаторов прокаспаз 3, 6 и/или 7 и их производным, их фармацевтическим композициям, способам применения и способам получения указанных соединений. Согласно одному объекту изобретения соединения применимы для лечения раковых и неопластических заболеваний.
EA201001143A 2008-01-11 2009-01-09 Активаторы прокаспаз "исполнителей" 3, 6 и 7 EA201001143A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2060808P 2008-01-11 2008-01-11
PCT/US2009/030680 WO2009089508A1 (en) 2008-01-11 2009-01-09 Activators of executioner procaspases 3, 6 and 7

Publications (1)

Publication Number Publication Date
EA201001143A1 true EA201001143A1 (ru) 2011-02-28

Family

ID=40853483

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201001143A EA201001143A1 (ru) 2008-01-11 2009-01-09 Активаторы прокаспаз "исполнителей" 3, 6 и 7

Country Status (11)

Country Link
US (1) US8642788B2 (ru)
EP (1) EP2237784A1 (ru)
JP (1) JP2011509939A (ru)
CN (1) CN101965189A (ru)
AU (1) AU2009203977A1 (ru)
BR (1) BRPI0907162A2 (ru)
CA (1) CA2711603A1 (ru)
EA (1) EA201001143A1 (ru)
IL (1) IL206901A0 (ru)
MX (1) MX2010007548A (ru)
WO (1) WO2009089508A1 (ru)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140106602A (ko) * 2011-11-30 2014-09-03 솔베이(소시에떼아노님) 멜드럼산의 플루오르화 유도체, 그 제조 방법, 및 용매 첨가제로서의 그의 용도
AU2013225682B2 (en) * 2012-03-02 2016-04-14 The Board Of Trustees Of The University Of Illinois Potent anticancer activity via dual compound activation
RU2659936C2 (ru) 2012-03-06 2018-07-04 Зэ Борд оф Трастиз оф зэ Юниверсити оф Иллинойс Активация прокаспазы-3 с помощью комбинированной терапии
MX359209B (es) 2012-03-06 2018-09-19 Univ Illinois Terapia de combinacion de procaspasa para gliobastoma.
US9518038B2 (en) 2012-09-27 2016-12-13 Shandong Yingdong Yinghao Biotechnology, Inc. Condensation product of theanine derivative and carboxylic acid coumarin derivative, its intermediate, preparation method and use thereof
SI2953942T1 (en) 2013-02-06 2018-03-30 Bayer Cropscience Ag Halogen-substituted pyrazole derivatives such as pesticides
TWI688557B (zh) 2013-11-27 2020-03-21 德商拜耳動物保健有限公司 用於製備５-氟-１ｈ-吡唑之方法（一）
US10273226B2 (en) 2014-01-03 2019-04-30 Bayer Animal Health Gmbh Pyrazolyl-heteroarylamides as pesticides
KR102540220B1 (ko) 2014-08-19 2023-06-02 바이엘 애니멀 헬스 게엠베하 헥사플루오로프로펜으로부터 5-플루오로-1h-피라졸의 제조 방법
EP3268353B1 (de) 2015-03-10 2020-09-09 Bayer Animal Health GmbH Pyrazolyl-derivate als schädlingsbekämpfungsmittel
EP3133065A1 (en) 2015-08-21 2017-02-22 Merck Patent GmbH Compounds for optically active devices
EP3363793A1 (en) 2017-02-15 2018-08-22 Merck Patent GmbH Hydrophobic compounds for optically active devices
EP3363786A1 (en) 2017-02-15 2018-08-22 Merck Patent GmbH Compounds for optically active devices
CN106946897B (zh) * 2017-02-28 2018-10-23 牡丹江医学院 一种治疗胆囊炎的药物及其应用
CA3082575A1 (en) 2017-11-17 2019-05-23 The Board Of Trustees Of The University Of Illinois Cancer therapy by degrading dual mek signaling
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
TW202100520A (zh) 2019-03-05 2021-01-01 美商英塞特公司 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
WO2020223558A1 (en) 2019-05-01 2020-11-05 Incyte Corporation Tricyclic amine compounds as cdk2 inhibitors
CR20220066A (es) 2019-08-14 2022-11-28 Incyte Corp Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
CN115298177A (zh) 2019-10-11 2022-11-04 因赛特公司 作为cdk2抑制剂的双环胺
US20230092441A1 (en) * 2019-12-24 2023-03-23 The Regents Of The University Of California Compositions and methods for treating cancer and improving epithelial homeostasis
EP4153598A1 (en) 2020-05-20 2023-03-29 AMO Ireland Azacoumarin and azathiocoumarin derivatives for use in optically active devices
CN113024499A (zh) * 2021-03-17 2021-06-25 河南中烟工业有限责任公司 一种香豆素-3-羧酸类化合物的绿色合成方法
CA3220039A1 (en) 2021-06-14 2022-12-22 Jr. David St. Jean Urea derivatives which can be used to treat cancer
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6342516B1 (en) * 1998-07-31 2002-01-29 Nippon Soda Co., Ltd. Phenylazole compounds, process for producing the same and drugs for hyperlipemia
AU2001277731A1 (en) * 2000-08-09 2002-02-18 Welfide Corporation Fused bicyclic amide compounds and medicinal use thereof
US20030229132A1 (en) * 2002-02-12 2003-12-11 Jack Nguyen Small molecule modulators of apoptosis
KR100440588B1 (ko) * 2002-06-10 2004-07-19 한국전자통신연구원 계층적 구조를 지원하는 직렬 버스형 형상 인식 및 경보장치
WO2007124617A1 (fr) * 2006-04-28 2007-11-08 Institute Of Mataria Medica, Chinese Academy Of Medical Sciences Dérivés de coumarine, leurs procédés de préparation, compositions pharmaceutiques et utilisations
AU2008345225A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms

Also Published As

Publication number Publication date
BRPI0907162A2 (pt) 2015-07-07
CN101965189A (zh) 2011-02-02
CA2711603A1 (en) 2009-07-16
WO2009089508A1 (en) 2009-07-16
EP2237784A1 (en) 2010-10-13
US8642788B2 (en) 2014-02-04
JP2011509939A (ja) 2011-03-31
IL206901A0 (en) 2010-12-30
AU2009203977A1 (en) 2009-07-16
US20110021522A1 (en) 2011-01-27
MX2010007548A (es) 2010-11-25

Similar Documents

Publication Publication Date Title
EA201001143A1 (ru) Активаторы прокаспаз "исполнителей" 3, 6 и 7
NO2017019I2 (no) Enzalutamid eller et farmasøytisk akseptabelt salt derav
CY1120617T1 (el) 1,2,5-οξαδιαζολια ως αναστολεις 2,3-διοξυγενασης ινδολοαμινης
MY157661A (en) Bendamustine pharmaceutical compositions
EA201101650A1 (ru) Новые производные пиримидина и их применение в лечении злокачественных новообразований и последующих заболеваний
CY1118061T1 (el) Δικυκλικα παραγωγα heterocyclyl σαν καταστολεις κινασης (kinase) fgfr για θεραπευτικη χρηση
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
PH12014500053A1 (en) Proteasome inhibitors
UA101493C2 (ru) Производные азетидина и циклобутана как ингибиторы jak
MX2009006706A (es) Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.
EA200870415A1 (ru) Хиназолины для ингибирования pdk 1
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
UA107783C2 (en) Isoindoline compounds for use in treating cancer
MX2009006466A (es) Metodos de tratamiento de cancer con inhibidores del receptor del factor 1 de crecimiento similar a la insulina.
EA201001639A1 (ru) Композиции и способы их получения и применения
TW200730515A (en) N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
CL2008000670A1 (es) Compuestos derivados de tiazolidindionas y oxazolidindionas sustituidas; composicion farmaceutica; proceso de preparacion de la composicion farmaceutica; y uso en el tratamiento de enfermedades tales como artritis reumatoide, epoc, cancer, entre otras.
MY177111A (en) Substituted amide derivatives and methods of use
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
EA201171435A1 (ru) Твердые фармацевтические композиции и способы их получения
UA94036C2 (ru) Фармацевтическая композиция бендамустина, предназначенная для лиофилизации
IL171974A0 (en) Tetrahydrocarbazole derivatives and their pharmaceutical use
CL2009000727A1 (es) Compuestos derivados de n-hidroxi-3-fenilprop-2-enemida y n-hidroxi-3-fenilpropanamida sustituidos; inhibidores de la enzima desacetilasa; su composicion farmaceutica; utiles en el tratamiento del cancer, tumores, psoriasis, alzheimer, entre otras.
CY1115725T1 (el) Ενωσεις, συνθεσεις και μεθοδοι για την θεραπευτικη αγωγη των βητα-αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака